Veeva Expands Customer Data in New Zealand to Enhance HCP Engagements
Veeva teams with Medidata Services Ltd. to provide sales reps access to over 65,000 HCP and HCO records
Veeva OpenData spans more than 20 million healthcare professionals and organisations globally. Through this latest expansion, life sciences companies with commercial teams in New Zealand will have access to regional HCP and HCO data. This integrated solution allows commercial teams to have an accurate view of New Zealand HCPs in Veeva CRM, to improve engagement.
"We are excited to be joining forces with Veeva to provide life sciences organisations with best-in-class New Zealand customer data," said Helen Roos, business manager at Medidata. "The relationship will provide us with access to Veeva Network, a world class database management platform, that will further enhance our data management services to customers."
"Quality customer data is foundational to commercial operations and yet most life sciences organisations are not getting what they need ' said Alex Paris, general manager, Veeva APAC. "We've teamed up with Medidata Services Ltd to help improve customer engagements in New Zealand through better multichannel interactions using quality customer data."
Veeva OpenData provides comprehensive and accurate HCP, HCO, affiliations, email, and compliance data, right where customers need it. Veeva OpenData can help customers achieve greater commercial success and enable everything from multichannel customer engagement to compliant interaction. Today, Veeva OpenData provides access to approximately 20 million HCPs and their HCO affiliations, covering all specialties and classes of trade, spanning 41countries.
For more on Veeva OpenData, visit: veeva.com/ap/products/opendata/
Stay updated on the latest Veeva news on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations," in the company’s filing on Form 10-Q for the period ended October 31, 2017. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov ---.
